Sign up
Quantellect · Congress · Issuer Profile
NYSE: DGXQuest Diagnostics Incorporated
HealthcareMkt Cap $28.56BCongress ownership rank #202

Quest Diagnostics Incorporated Congressional Trading

According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 131 trades in Quest Diagnostics Incorporated (NYSE: DGX) since 2013, across 20 members, worth an estimated $1.9M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 64 buys against 67 sells, a modestly sell-led skew, with Democratic members responsible for 35% of the trades and Republican members 65%. The most recent disclosure shown was filed November 2026, and Rohit Khanna has filed the most DGX transactions among those shown, with 4. Other recent filers include Alan Armstrong. One notable disclosed move was a purchase by Rohit Khanna on January 29, 2026, up 43.0% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. Quest Diagnostics Incorporated's current Quantellect Tide Score is 60 out of 100 (High Tide), Top 22% of universe (3865); the Tide Score is generated algorithmically from public filings and market data and is not investment advice. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Quest Diagnostics Incorporated (DGX) stock overview and the complete trade table below.

Data updated

Trades
6
Politicians
2
Filings
5
Disclosed Vol
$48.00K
Buys
4
67%
Sells
2
33%

Price & congressional trade timeline

Party breakdown

Quest Diagnostics congressional trading activity

PoliticianPublishedTradedFiled AfterTypeSizeReturnOwner
Nov 5, 2026Oct 7, 202629 daysSell
$1,001 - $15,000
+14.37%Spouse
Oct 7, 2026Sep 4, 202633 daysBuy
$1,001 - $15,000
+9.51%Spouse
Jul 21, 2026Mar 30, 2026113 daysBuy
$1,001 - $15,000
+32.29%Self
Jul 21, 2026Mar 27, 2026116 daysBuy
$1,001 - $15,000
+33.40%Self
Mar 9, 2026Feb 17, 202620 daysSell
$1,001 - $15,000
+26.92%Spouse
Feb 6, 2026Jan 29, 20268 daysBuy
$1,001 - $15,000
+43.03%Spouse
Go to

Quest Diagnostics (DGX) congressional trading FAQ

Can members of Congress legally trade Quest Diagnostics (DGX) stock?

Yes. Members of Congress are permitted to trade individual stocks, including Quest Diagnostics (DGX), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.

Are congressional Quest Diagnostics (DGX) trades public?

Yes. Every congressional trade in Quest Diagnostics (DGX) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.

How many times has Congress traded Quest Diagnostics (DGX)?

Members of Congress have disclosed 131 trades in Quest Diagnostics (DGX) worth $1.9M across 20 members, according to public STOCK Act filings.

Which members of Congress have traded Quest Diagnostics (DGX)?

Recent and active filers of Quest Diagnostics (DGX) disclosures include Rohit Khanna, Alan Armstrong. The full member-by-member trade list is on this page.

Do Democrats or Republicans trade Quest Diagnostics (DGX) more?

Across disclosed Quest Diagnostics (DGX) trades, 35% were by Democrats and 65% by Republicans, led by Republicans (65%).

What is the most recent congressional Quest Diagnostics (DGX) trade?

The most recent disclosed Quest Diagnostics (DGX) filing reported a sell by Rohit Khanna, filed Nov 4, 2026.

What is Quest Diagnostics (DGX)'s Tide Score?

Quest Diagnostics (DGX) has a Quantellect Tide Score of 60 (High Tide). The Tide Score is a 0-100 read blending price forecast, smart-money flow, technicals, and social sentiment; higher is more bullish.

Browse all stocks Congress tradesCongressional trading overviewQuest Diagnostics (DGX) stock overview

Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.